Shrinidhi Nathany: Why the Theriome Matters More Than We Think
Shrinidhi Nathany, Consultant Molecular Hematology and Oncology at Fortis Memorial, posted on LinkedIn:
“Sunday learning with the boss Dr. Rahul Bhargava
After a break back with a bang.. with more new concepts
As i started a thread on theriome, i will continue that today
Why the Theriome Matters More Than We Think
We often ask why patients with the same diagnosis and similar mutations have very different outcomes.
The answer often lies in the theriome.
The theriome influences how aggressively a tumour behaves, how it escapes the immune system and how it responds or fails to respond to therapy. In hematologic malignancies, the bone marrow and lymphoid niche can actively protect malignant cells from chemotherapy and targeted drugs.
This is why genomics alone is sometimes not enough. To truly understand cancer behaviour, we must also understand the ecosystem in which the cancer lives.”
Stay informed with Hemostasis Today.
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID
-
Dec 16, 2025, 23:14Shrinidhi Nathany: MRD in AML – From a Test to a Treatment Decision
-
Dec 16, 2025, 23:04Jim Hoffman: Timely Extracorporeal NET Removal Therapy Should Be Tried on High-Risk Patients
-
Dec 16, 2025, 22:16Wolfgang Miesbach – Targeting VEGF to Stop GI Bleeding: Systemic Bevacizumab
-
Dec 16, 2025, 17:14Piotr Czempik Honored for His Work on Cost Reduction in Blood Transfusions